Merck and Moderna report 42% reduction in melanoma death risk with personalised vaccine
Top-line results from a late-stage trial show intismeran combined with Keytruda significantly lowers recurrence and mortality rates compared to standard care alone.
Key points
- The personalised mRNA vaccine reduced the risk of death or recurrence by 42 percent in a Phase 3 trial.
- Merck and Moderna announced the results on Thursday after an early leak broke the embargo for the European Society of Medical Oncology conference.
- The trial involved 1,137 patients with stage IIB–IV melanoma who had undergone surgery prior to receiving the combination therapy.
Pharmaceutical partners Merck and Moderna announced on Thursday that their personalised mRNA cancer vaccine, intismeran, significantly reduced the risk of death or recurrence in patients with melanoma. The companies revealed top-line results from a late-stage trial, showing a 42 percent reduction in these risks compared to standard treatment alone. This announcement follows an early report by an oncology news site that broke the embargo ahead of the scheduled presentation at the European Society of Medical Oncology conference in Madrid.
Root cause
The vaccine’s efficacy stems from its personalised approach to targeting cancer cells. Intismeran, also known as mRNA-4157, uses synthetic mRNA containing the unique genetic coding for up to 34 mutations found in a patient’s own cancer cells. Researchers produce these tailored vaccines by comparing the genetic sequences of a patient’s cancer cells with those of their healthy cells. This process allows them to identify cancer-specific mutations that can help the immune response selectively target only the malignant cells, rather than affecting healthy tissue.
Attack path
The trial design involved randomising 1,137 patients with stage IIB–IV melanoma, all of whom had their cancer surgically removed before entering the study. Participants were assigned in a 2-1 ratio to receive either a combination treatment or the standard treatment alone. The combination group received the personalised mRNA vaccine alongside Merck’s established monoclonal antibody cancer treatment, Keytruda. The control group received only Keytruda. This structure allowed researchers to isolate the impact of adding the personalised vaccine to the existing standard of care.
Affected versions
The data presented applies specifically to patients with stage IIB–IV melanoma who had undergone surgical removal of their tumours. The results are derived from a Phase 3 clinical trial involving 1,137 participants. The full dataset has been accepted for publication in the New England Journal of Medicine. The companies are now engaging with regulatory authorities to seek approval for the vaccine, marking a significant step towards potential clinical adoption for this specific patient demographic.
Mitigation
- Monitor regulatory updates from health authorities regarding the approval status of intismeran.
- Review internal oncology treatment protocols to assess potential integration of personalised mRNA therapies.
- Engage with pharmaceutical partners to understand supply chain requirements for personalised vaccine production.
- Prepare clinical teams for the genetic sequencing and data analysis processes required for patient-specific vaccine creation.
What it means for organisations
Healthcare providers should evaluate their capacity to handle personalised medicine workflows, including genetic sequencing and data management. Clinical teams need to understand the operational changes required for administering combination therapies. Procurement departments should assess supplier readiness for producing individualised vaccines. Leadership must consider how this technology might shift long-term treatment strategies and resource allocation. Internal communication plans should address staff training needs for new diagnostic and therapeutic procedures to ensure smooth implementation once approved.
Background: Supply chain attacks
Supply chain attacks in cyber security exploit the trust you place in third-party software components. Attackers inject malicious code into legitimate updates or build pipelines. You receive the payload as if it were benign. Defending requires verifying code origins, isolating build environments and treating all external inputs as hostile.
Read the full guide: Supply chain attacks in cyber security: how they work and how to stop them
What to do and how to stay safe: Merck
- Check with regulatory bodies for the latest approval status and guidelines for personalised mRNA vaccines.
- Assess current infrastructure for genetic sequencing and data privacy compliance.
- Review existing treatment protocols to identify opportunities for integrating new therapeutic options.
- Engage with pharmaceutical partners to understand supply chain and production timelines.
General security guidance from the TechSec Observer newsroom. It is not confirmed advice from the organisations named in this story.
Frequently asked questions
What is the name of the personalised mRNA vaccine?
The vaccine is called intismeran, also known as mRNA-4157.
How many patients were included in the Phase 3 trial?
The trial included 1,137 patients with stage IIB–IV melanoma.
What was the standard treatment used in the trial?
The standard treatment was Merck’s monoclonal antibody cancer treatment, Keytruda.
